Earnings ·
Prime Medicine reported second quarter 2026 financial results with a net loss of $42.1 million and cash reserves of…
PRMEPrime Medicine, Inc.
Prime Medicine reported second quarter 2026 financial results with a net loss of $42.1 million and cash reserves of $108.8 million as of June 30, 2026. The company announced favorable arbitration resolution with Beam Therapeutics affirming its rights to PM647 for Alpha-1 Antitrypsin Deficiency, with IND/CTA submission expected in Q3 2026. FDA cleared the IND and CTA for PM577a in Wilson disease, establishing a global Phase 1/2 program with initial data anticipated in 2027. The FDA also granted Regenerative Medicine Advanced Therapy designation to PM359 for chronic granulomatous disease, supporting a planned BLA submission in H1 2027. Prime Medicine operates as a biotechnology company developing gene editing therapies.